item management s discussion and analysis of financial condition and results of operations since its inception in september  neurogen has been engaged in the discovery and development of drugs 
the company has not derived any revenue from product sales and  excluding the effect of one time license fees received in from schering plough and american home products and from schering plough and pfizer in  expects to incur significant losses in most years prior to deriving any such product revenues 
revenues to date have come from three collaborative research agreements entered into with pfizer  one collaboration with schering plough  one license agreement with american home products and from interest income 
results of operations results of operations may vary from period to period depending on numerous factors  including the timing of income earned under existing or future strategic alliances  joint ventures or financings  if any  the progress of the company s research and development projects  technological advances and determinations as to the commercial potential of proposed products 
neurogen expects research and development costs to increase significantly over the next several years as its drug development programs progress 
in addition  general and administrative expenses necessary to support the expanded research and development activities are expected to increase for the foreseeable future 
years ended december   and the company s operating revenues decreased to million for the year ended december  from million for the same period in the decrease in operating revenues in compared to is mainly due to a decrease in license fees 
the company s results include the recognition of a previously unearned license fee of million received from schering plough in july for access to a portion of neurogen s combinatorial chemistry libraries and 
million in license fees from american home products received in november in june and november  the company received  and recognized as revenue  million and million in one time license fees in connection with entering into the schering plough agreement and the pfizer agreement  respectively 
due primarily to these license fees  the company s operating revenues increased to million for the year ended december  compared to million in research and development revenues increased million  or percent  to million for the year ended december  due to the commencement of research funding under the schering plough agreement in the third quarter of and the pfizer agreement in the fourth quarter of in addition to the quarterly research funding payments received from pfizer  research and development revenue for the year ended december  includes reimbursements from pfizer of certain development expenses as part of the cost sharing arrangement on the npy obesity project 
research revenues increased by million or percent from to these increases are due to the commencement of the pfizer agreement in the third quarter of  the schering plough agreement in the third quarter of and the pfizer agreement in the fourth quarter of research and development costs increased percent to million for the year ended december  as compared to the same period in research and development costs increased percent to million in compared to these increases are due primarily to an increase in research and development personnel to staff the company s growing portfolio of drug development programs and an expansion of neurogen s drug discovery capabilities through its growing aidd accelerated intelligent drug design program 
research and development costs represented percent  percent and percent of total operating expenses for the years ended december   and  respectively 
general and administrative expenses increased percent to million in from million in and percent from million in the increases in both years were due primarily to an increase in administrative activities and the addition of related facilities to support the company s expanded research programs 
other income  consisting primarily of interest income and gains and losses from marketable securities  was million in  million in and million in  respectively 
the increase in both years was due primarily to a higher level of invested funds 
the company recognized net income of million for the year ended december   net income of million for the year ended december  and a net loss of million in the decrease in net income in is due mainly to a decrease in license fees from schering plough 
the change in net income in is primarily due to revenues resulting from the above noted one time license fees of million from schering plough and million from pfizer and the million increase in investment income 
liquidity and capital resources at december  and  cash  cash equivalents and marketable securities were in the aggregate million and million  respectively 
the increase in was due to an increase in receipts from corporate partner funding and an increase in investment income 
the company s aggregate level of cash  cash equivalents and marketable securities have fluctuated in the past and are expected to fluctuate in the future as a result of the factors described below 
neurogen s cash requirements to date have been met by the proceeds of its financing activities  amounts received pursuant to collaborative arrangements and interest earned on invested funds 
the company s financing activities include three private placement offerings of its common stock prior to its initial public offering  underwritten public offerings of the company s common stock in  and  and the private sale of common stock to pfizer in connection with entering into the pfizer agreements and to american home products in the american home products agreement 
total funding received from these financing activities was approximately million 
the company s expenditures have been primarily to fund research and development and general and administrative expenses and to construct and equip its research and development facilities 
in the first quarter of  the company entered into the pfizer agreement pursuant to which pfizer made a million equity investment in the company 
under this agreement  the company received million in each year from through neurogen could also receive milestone payments of up to million if certain development and regulatory objectives are achieved regarding its products subject to the collaboration 
in return  pfizer received the exclusive rights to manufacture and market collaboration anxiolytics and cognition enhancers that act through the family of receptors which interact with the neuro transmitter gamma aminobutyric acid  or gaba  and for which it will pay neurogen royalties based upon net sales levels  if any  for such products 
as of december   pfizer had provided million of research funding to the company pursuant to the pfizer agreement  in addition to its million equity investment in neurogen and pfizer entered into their second collaborative agreement  the pfizer agreement  in july  pursuant to which pfizer made an additional million equity investment in the company 
under this agreement  the company is scheduled to receive approximately million during the three year period which commenced july   to fund neurogen s sleep disorder program 
neurogen could also receive milestone payments of up to million if certain development and regulatory objectives are achieved regarding its products subject to the collaboration 
as part of this second collaboration  pfizer received the exclusive rights to manufacture and market gaba based sleep disorder products for which it will pay neurogen royalties depending upon net sales levels  if any 
as of december   pfizer had provided million of research funding to the company pursuant to the pfizer agreement  in addition to its million equity investment in in  neurogen and pfizer extended the research program under the pfizer agreement and pfizer agreement agreements and neurogen expects to receive  in each of and for research and development funding of the company s anxiolytic and cognitive enhancer projects to fund neurogen s research in its anxiolytic anxiety reducing drugs  cognitive enhancer and sleep disorder programs 
under both the pfizer agreement and the pfizer agreement  in addition to making the equity investments and the research and milestone payments noted above  pfizer is responsible for funding the cost of all clinical development and the manufacturing and marketing  if any  of drugs developed from the collaborations 
neurogen and pfizer entered into their third collaborative agreement  the pfizer agreement  in november  pursuant to which pfizer made an additional million equity investment in the company bringing pfizer s ownership of the company s common stock up to and paid a million license fee 
the company is scheduled to receive approximately million during the three year period which commenced november   to fund neurogen s neuropeptide y npy eating disorders program and may receive up to an additional million per year for a fourth and fifth year should pfizer exercise its option to extend the research program under the collaboration 
neurogen could also receive milestone payments of up to approximately million if certain development and regulatory objectives are achieved regarding its products subject to the collaboration 
as part of this third collaboration  pfizer received the exclusive worldwide rights to manufacture and market npy based collaboration compounds  subject to certain rights retained by neurogen 
pursuant to the pfizer agreement  neurogen will fund a minority share of early stage development costs and has retained the right to manufacture any collaboration products in nafta countries and has retained a profit sharing option with respect to product sales in nafta countries 
if neurogen exercises the profit sharing option  it will fund a portion of the cost of late stage clinical trials and marketing costs and in return receive a specified percentage of any profit generated by sales of collaboration products in nafta countries 
if neurogen chooses not to exercise its profit sharing option  pfizer would pay neurogen royalties on drugs marketed in nafta countries and would fund a majority of early stage and all late stage development and marketing expenses 
in either case neurogen would be entitled to royalties on drugs marketed in non nafta countries 
as of december   pfizer had provided  in research funding including  in unearned revenues pursuant to the pfizer agreement 
in june  neurogen and schering plough entered into the schering plough agreement to collaborate in the discovery and development of drugs for the treatment of schizophrenia and other disorders which act through the dopamine family of receptors 
pursuant to the schering plough agreement  the company received one time license fees of million for rights relating to neurogen s dopamine program and million in and for the right to test certain of neurogen s combinatorial chemistry libraries in selected non cns assays 
neurogen has received or expects to receive an aggregate of approximately million during the two year period which commenced june   for research and development funding of the company s dopamine program 
the company may receive additional research and development funding of up to million per year for three additional one year periods depending on whether and the extent to which schering plough exercises its right to extend the research program under the collaboration 
in march  neurogen received notice from schering plough of its election to extend the research program under the schering plough agreement for an additional one year period  through june  pending the parties adoption of a formal research plan relating to the extension period 
neurogen could also receive milestone payments of up to approximately million if certain development and regulatory objectives are achieved regarding its products subject to the collaboration 
in return  schering plough received the exclusive worldwide license to market products subject to the collaboration and neurogen retained the rights to receive royalties based on net sales levels  if any  and an option to manufacture products for the united states market 
as of december   schering plough had provided million in research funding including  in unearned revenue pursuant to the schering plough agreement 
in addition to the payments described above  schering plough is responsible for funding the cost of all clinical development and marketing  if any  of drugs subject to the collaboration 
in the forth quarter of neurogen entered into an agreement with american home product corporation  acting through its wyeth ayerst laboratories division 
under the terms of the agreement neurogen received  in license fees for adci  a small molecule pharmaceutical that neurogen has been developing for the treatment of epilepsy and related disorders  and  for  shares of common stock 
neurogen may receive up to an additional million in the form of license fees  equity investment and milestone payments on world wide sales of adci 
the company plans to use its cash balance for its research and development activities  working capital and general corporate purposes 
neurogen anticipates that its current cash balance  as supplemented by research funding pursuant to the pfizer agreements and the schering plough agreement  will be sufficient to fund its current and planned operations through however  neurogen s funding requirements may change and will depend upon numerous factors  including but not limited to  the progress of the company s research and development programs  the timing and results of preclinical testing and clinical studies  the timing of regulatory approvals  technological advances  determinations as to the commercial potential of its proposed products  the status of competitive products and the ability of the company to establish and maintain collaborative arrangements with others for the purpose of funding certain research and development programs  conducting clinical studies  obtaining regulatory approvals and  if such approvals are obtained  manufacturing and marketing products 
the company anticipates that it may augment its cash balance through financing transactions  including the issuance of debt or equity securities and further corporate alliances 
no arrangements have been entered into for any future financing and no assurances can be given that adequate levels of additional funding can be obtained on favorable terms  if at all 
as of december   the company had approximately  of net operating loss carryforwards available for federal income tax purposes which expire from the years through the company had approximately  of connecticut state tax net operating loss carryforwards as of december  which expire in the years through because of change in ownership provisions of the tax reform act of  the company s utilization of its net operating loss carryforwards may be subject to an annual limitation in future periods 

